BioCentury
ARTICLE | Clinical News

Antineoplastons: Phase II data

April 13, 2015 7:00 AM UTC

A U.S. Phase II trial in 19 evaluable patients with newly diagnosed anaplastic astrocytoma showed that ANP every 4 hours led to a complete response rate of 21% and a stable disease rate of 26%. The tr...